Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...

In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.

The FDA first approved Zepbound to treat obesity in ... Medicare does not cover weight-loss drugs specifically for obesity, although the medications can be covered for conditions exacerbated ...

The first medication for obstructive sleep apnea has been approved by the U.S. Food and Drug Administration (FDA). On Dec. 20 ... "Zepbound promotes weight loss and has been shown to reduce ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

The FDA's approval is based on data from ... those with disabilities are barred from covering weight-loss treatments, though the Biden administration has proposed to expand the coverage of ...